Special Issue "Chemotherapeutic Agents"
A special issue of Pharmaceuticals (ISSN 1424-8247).
Deadline for manuscript submissions: closed (31 August 2013)
Dr. Ashkan Emadi
Leukemia and Hematologic Malignancies, Marlene & Stewart Greenebaum Cancer Center, School of Medicine, University of Maryland, Baltimore, Maryland 21201, USA
Interests: acute leukemia; myelodysplastic syndrome; myeloproliferative neoplasms; metabolic pathways and metabolism in hematologic malignancies; glutamine metabolism in cancer; anti-neoplastic effects of naphthoquinones; Chemotherapeutic Design and Discovery for Hematologic and Solid Neoplasms
Dr. Dhimant Desai
Department of Pharmacology, Pennsylvania State University College of Medicine, 500 University Drive Hershey, PA 17033, USA
Interests: Synthesis of chemotherapeutic and chemopreventive agents; colon; melanoma; prostate; pancreatic; lung; drug discovery and delivery
The journal “Pharmaceuticals” is planning to publish a special issue covering the topic “Chemotherapeutic Agents” and we are inviting you to contribute an article to this volume. Cancer survival has improved drastically in the last four decades. This is the culmination of many factors, most importantly endless work of scientists and clinicians to better understand the pathophysiology of neoplastic cells. Cancer is an extremely heterogeneous disease with several distinct clinical, pathological, genetic, and molecular features. Although significant advances have been accomplished to treat a few cancers such as chronic myelogenous leukemia (CML), acute promyelocytic leukemia (APL), testicular cancer and lymphomas, much more basic, translational and clinical research are needed to fight other hematologic and solid neoplasms. The novel chemotherapeutic agents have revolutionaized our ability to fight cancer. The design and mechanisms of action of the chemotherapeutic agents, their biological activity screening in vitro and in vivo, and subsequent clinical trials are ongoing need of modern industrialized societies. We would like you to share your contributions to the advances and opportunities in this burgeoning field of cancer chemotherapy drug discovery and development for this special issue. Areas of interest include basic and clinical research on novel:
- Alkylating agents
- Plant alkaloids including vincas, taxanes, podophyllotoxins
- Topoisomerase inhibitors
- Kinase signaling pathways and inhibitors
- Intracellular Redox Modification
- Targeting Cancer Metabolic Pathways Modulators
- Monoclonal Antibodies
- Nanotechnology Drug Delivery
- Modulators of Tumor Microenvironments
- Metal- and Metalloid-based Chemotherapy Agents
- Epigenetic Modifications
Dr. Ashkan Emadi & Dr. Dhimant Desai
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed Open Access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 500 CHF (Swiss Francs). English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.